Search results for "Numa"
showing 10 items of 74 documents
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study
2019
Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease…
Familial Mediterranean Fever: an unusual cause of liver disease
2019
Abstract Background Familial Mediterranean Fever is an autoinflammatory disease typically expressed with recurrent attacks of fever, serositis, aphthous stomatitis, rash. Only a few reports describe the association with hepatic involvement. Case presentation We describe the clinical case of a child affected, since the age of 1 year, by recurrent fever, aphthous stomatitis, rash, arthralgia, associated with abdominal pain, vomiting, lymphadenopathy. The diagnosis of Familial Mediterranean Fever was confirmed by the genetic study of MEFV gene; the homozygous mutation M694 V in exon was documented. A partial control of attacks was obtained with colchicine. The child continued to manifest only …
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
2021
Abstract Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% o…
A CONFIGURAÇÃO INOVADORA DO PRINCÍPIO DA BOA ADMINISTRAÇÃO ENTRE PRIVADOS E AUTORIDADES PÚBLICAS NA UNIÃO EUROPÉIA
2017
O direito a uma boa administração pública é um dos direitos fundamentais da pessoa, garantido pelo artigo 41 da Carta dos direitos fundamentais da União Europeia, que, em 2009, por força do Tratado de Lisboa, tornou-se juridicamente vinculante com o mesmo valor de fonte primária dos Tratados europeus. Ele é definido como o direito de cada pessoa (física e jurídica) de receber, por parte da autoridade pública, em relação às questões que se lhe refiram, um tratamento imparcial, equitativo e num prazo razoável. Inclui, também, os seguintes direitos de natureza procedimental: a ser ouvida, antes de, a seu respeito, ser tomada qualquer medida individual que a afete desfavoravelmente; a ter acess…
P293 Loss of response after first-line biologic therapy in patients with inflammatory bowel disease: practical approach and management
2020
Abstract Background Anti-tumour necrosis factors (anti-TNFs) have greatly improved therapeutic strategies for the treatment of inflammatory bowel diseases (IBDs). However, a significant number of patients do not respond or lose response over time (LOR). The aim of this retrospective prospective study was to evaluate patients (patients) treated with anti-TNFs as first-line treatment, with subsequent LOR, defined as recurrence of disease activity during maintenance therapy. We determine the prevalence of LOR and its management. Methods Three-hundred forty patients with IBDs were included: 65% had Crohn’s disease and 35% ulcerative colitis. Mean age at diagnosis was 31,5 years and medium time …
FRI0696 Patient activation and adherence to biological therapy: preliminary results
2018
Background: Medication non-adherence is associated with treatment failure. Some authors show a positive relationship between patient activation and both, adherence to treatment for chronic conditions and improved outcomes. Objectives: To present preliminary results of a study measuring adherence to biological therapy and its relationship with the Patient Activation Measure (PAM) in the outpatient setting. Methods: Ambispective longitudinal observational descriptive study in a general tertiary university hospital. Patients on treatment with the same biological drug for ≥6 months were included in order of arrival. Patients with some degree of mental disability, which prevented understanding o…
Trouble always comes in threes: three mutations for three auto inflammatory genes in a child and in his father
2014
The coexistence of mutations in more than one gene, linked to Autoinflammatory Diesases, can confuse and make difficult the diagnosis and management of these patients, especially in childhood, when the clinical history is still brief.
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
2015
Summary Background Interleukin 13 is a central mediator of asthma. Tralokinumab is a human interleukin-13 neutralising monoclonal antibody. We aimed to assess the efficacy and safety of two dosing regimens of tralokinumab in patients with severe uncontrolled asthma. Methods We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 2b study at 98 sites in North America, South America, Europe, and Asia. Patients aged 18–75 years with severe asthma and two to six exacerbations in the previous year were randomly assigned (1:1), via an interactive voice-response or web-response system, to one of two dosing regimen groups (every 2 weeks, or every 2 weeks for 12 wee…
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…
2021
AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…
Lokāla anestētiķa darbības ilguma izvērtēšana, atkarībā no devas pleca nervu pinuma blokā
2016
Pleca nervu pinuma bloks ir efektīva metode, kas ļauj novērst pēcoperācijas sāpes, diskomforta sajūtu un stresu. Daudzās anesteziologu vadlīnijās eksistē konkrēta medikamenta deva, ar kuru varētu veikt sekmīgu pleca pinuma bloku un nodrošināt pēcoperācijas analgēziju jeb “rekomendēta maksimāla deva”. Maksimālās devas pielietošana, palielina nevēlamo toksicitātes reakciju attīstības risku. Darba mērķis ir atrast minimālu efektīvu ropivakaīna devu, kas nodrošinās sekmīgu bloku.Pētījumā tika iekļauti 25 pacienti kas tika randomizēti sadalīti piecās grupās, kur katrai grupai bija sava 0,375% ropivakaīna deva.Analgēzijas ilgums katrā grupā ir atšķirīgs: 5 mililitru grupā 5 ± 3.54 stundas( p 0.1)…